194 related articles for article (PubMed ID: 37357618)
1. Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy.
Wei L; Zhang Q; Zhong C; He L; Zhang Y; Armaly AM; Aubé J; Welch DR; Xu L; Wu X
Mol Oncol; 2023 Oct; 17(10):1962-1980. PubMed ID: 37357618
[TBL] [Abstract][Full Text] [Related]
2. miR-1205/DNAJB1 reverses docetaxel chemoresistance in human triple negative breast carcinoma cells via regulation of mutp53/TAp63 signaling.
Yin Y; Zhang J; Ma T; Chen D; Lu D
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(1):37-46. PubMed ID: 35130632
[TBL] [Abstract][Full Text] [Related]
3. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
4. Quercetin Impairs HuR-Driven Progression and Migration of Triple Negative Breast Cancer (TNBC) Cells.
Umar SM; Patra S; Kashyap A; Dev J R A; Kumar L; Prasad CP
Nutr Cancer; 2022; 74(4):1497-1510. PubMed ID: 34278888
[TBL] [Abstract][Full Text] [Related]
5. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.
Mehta M; Basalingappa K; Griffith JN; Andrade D; Babu A; Amreddy N; Muralidharan R; Gorospe M; Herman T; Ding WQ; Ramesh R; Munshi A
Oncotarget; 2016 Oct; 7(40):64820-64835. PubMed ID: 27588488
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
[No Abstract] [Full Text] [Related]
7. Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells.
Jeon YW; Kim OH; Shin JS; Hong HE; Kim CH; Kim SJ
Cancer Res Treat; 2022 Jan; 54(1):157-173. PubMed ID: 33831291
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
9. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
Messeha SS; Noel S; Zarmouh NO; Womble T; Latinwo LM; Soliman KFA
Cancer Genomics Proteomics; 2023; 20(4):323-342. PubMed ID: 37400144
[TBL] [Abstract][Full Text] [Related]
10. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
11. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
[TBL] [Abstract][Full Text] [Related]
12. MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
Chaudhary S; Appadurai MI; Maurya SK; Nallasamy P; Marimuthu S; Shah A; Atri P; Ramakanth CV; Lele SM; Seshacharyulu P; Ponnusamy MP; Nasser MW; Ganti AK; Batra SK; Lakshmanan I
Breast Cancer Res; 2023 Mar; 25(1):25. PubMed ID: 36918912
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
14. IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
Liao J; Qin QH; Lv FY; Huang Z; Lian B; Wei CY; Mo QG; Tan QX
Sci Rep; 2023 Apr; 13(1):6211. PubMed ID: 37069240
[TBL] [Abstract][Full Text] [Related]
15. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
Zong B; Sun L; Peng Y; Wang Y; Yu Y; Lei J; Zhang Y; Guo S; Li K; Liu S
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036395
[TBL] [Abstract][Full Text] [Related]
16. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
17. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
18. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
19. Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer.
Ma J; Fan Z; Tang Q; Xia H; Zhang T; Bi F
Cell Death Dis; 2020 Jul; 11(7):530. PubMed ID: 32661222
[TBL] [Abstract][Full Text] [Related]
20. ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTOR.
Wan H; Li Z; Wang H; Cai F; Wang L
Clin Transl Oncol; 2021 Apr; 23(4):902-910. PubMed ID: 32939659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
